down arrow

Pieris Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7207951036
USD
93.80
2.21 (2.41%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

90.8694.77

52 Week

11.17106.05
Valuation
Technical
Day's Volume

CASH

57.6 k

Shareholding (Mar 2025)

FII

0.72%

Held by 8 FIIs

DII

79.45%

Held by 3 DIIs

Promoter

17.11%

How big is Pieris Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Pieris Pharmaceuticals, Inc. has a market capitalization of 238.34 million and reported net sales of 0.00 million with a net profit of -17.21 million over the latest four quarters. Shareholder's funds are 62.61 million, and total assets amount to 88.23 million.

As of Jun 18, Pieris Pharmaceuticals, Inc. has a market capitalization of 238.34 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -17.21 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 62.61 million, and total assets amount to 88.23 million.

Read More

What does Pieris Pharmaceuticals, Inc. do?

22-Jun-2025

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a market cap of USD 238.34 million, focused on developing innovative therapies. As of March 2025, it reported a net profit loss of USD 8 million and has no dividend yield.

Overview:<BR>Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, with a market capitalization of USD 238.34 million.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 238.34 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.36 <BR>Return on Equity: -30.71% <BR>Price to Book: 4.29<BR><BR>Contact Details:<BR>Address: 255 STATE STREET, 9TH FLOOR, BOSTON MA : 02109 <BR>Tel: ['1 857 2468998', '1 857 3629635'] <BR>Fax: 49 8161 1411444 <BR>Website: https://www.pieris.com/

Read More

Who are in the management team of Pieris Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Pieris Pharmaceuticals, Inc. includes Mr. James Geraghty (Independent Chairman), Mr. Stephen Yoder (President and CEO), and several Independent Directors: Dr. Ann Barbier, Dr. Peter Kiener, Mr. Christopher Kiritsy, Mr. Michael Richman, and Dr. Maya Said.

As of March 2022, the management team of Pieris Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. James Geraghty, who serves as the Independent Chairman of the Board.<BR>- Mr. Stephen Yoder, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Ann Barbier, who is an Independent Director.<BR>- Dr. Peter Kiener, who is also an Independent Director.<BR>- Mr. Christopher Kiritsy, another Independent Director.<BR>- Mr. Michael Richman, who serves as an Independent Director.<BR>- Dr. Maya Said, who is an Independent Director.<BR><BR>This team comprises a mix of leadership and independent directors, contributing to the governance of the company.

Read More

Is Pieris Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 15, 2025, Pieris Pharmaceuticals, Inc. is considered overvalued with a price-to-book ratio of 5.13 and a negative return on equity of -30.71%, reflecting significant financial concerns and a stark contrast to its peers, despite a year-to-date stock return of 87.83% overshadowed by a three-year decline of -84.93%.

As of 15 May 2025, Pieris Pharmaceuticals, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently overvalued, with a price-to-book ratio of 5.13 and a negative return on equity (ROE) of -30.71%. Additionally, the EV to EBITDA ratio stands at -12.36, reflecting ongoing losses and a lack of profitability.<BR><BR>In comparison to its peers, Pieris Pharmaceuticals shows a stark contrast, as companies like Elevation Oncology, Inc. and Enlivex Therapeutics Ltd. also do not qualify but have less severe valuations with EV to EBITDA ratios of 0.5869 and -0.2828, respectively. The company's stock performance has been volatile, with a year-to-date return of 87.83%, which, while impressive, is overshadowed by a 3-year decline of -84.93% compared to the S&P 500's 58.74% return in the same period. This further emphasizes the overvaluation of Pieris Pharmaceuticals in the current market context.

Read More

Is Pieris Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Pieris Pharmaceuticals, Inc. shows a bullish technical trend with strong momentum indicators, despite mixed monthly signals, having outperformed the S&P 500 significantly year-to-date and over the past year.

As of 5 September 2025, the technical trend for Pieris Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and KST. Daily moving averages also indicate a bullish stance. However, the monthly RSI shows a bearish signal, and both the weekly and monthly Dow Theory are mildly bullish. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 392.00% compared to the S&P 500's 12.22%, and over the past year, it has returned 265.35% against the S&P 500's 17.14%. Overall, the current technical stance is bullish with strong momentum indicators, despite some mixed signals on the monthly timeframe.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 603 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.17

stock-summary
Return on Equity

-50.10%

stock-summary
Price to Book

12.62

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
75.29%
0%
75.29%
6 Months
283.8%
0%
283.8%
1 Year
482.61%
0%
482.61%
2 Years
463.97%
0%
463.97%
3 Years
9280.0%
0%
9280.0%
4 Years
-63.13%
0%
-63.13%
5 Years
-60.12%
0%
-60.12%

Pieris Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Pieris Pharmaceuticals, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Pieris Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from the Bollinger Bands and KST. Daily moving averages also indicate a bullish stance. However, the monthly RSI shows a bearish signal, and both the weekly and monthly Dow Theory are mildly bullish. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 392.00% compared to the S&P 500's 12.22%, and over the past year, it has returned 265.35% against the S&P 500's 17.14%. Overall, the current technical stance is bullish with strong momentum indicators, despite some mixed signals on the monthly timeframe....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-4.40%
EBIT to Interest (avg)
-30.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.36
Sales to Capital Employed (avg)
0.94
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
49.46%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.13
EV to EBIT
-12.36
EV to EBITDA
-12.36
EV to Capital Employed
-10.44
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-30.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 6 Schemes (2.73%)

Foreign Institutions

Held by 8 Foreign Institutions (0.72%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -15.85% vs -182.76% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-7.90",
          "chgp": "-17.72%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "1.20",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.50",
          "val2": "-8.20",
          "chgp": "-15.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -193.05% vs 156.16% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-11.90",
          "chgp": "-18.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.50",
          "val2": "23.60",
          "chgp": "-106.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.40",
          "val2": "18.70",
          "chgp": "-193.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.30
-7.90
-17.72%
Interest
1.40
1.20
16.67%
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-9.50
-8.20
-15.85%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -15.85% vs -182.76% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-14.10
-11.90
-18.49%
Interest
4.30
0.00
Exceptional Items
-1.50
23.60
-106.36%
Consolidate Net Profit
-17.40
18.70
-193.05%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -193.05% vs 156.16% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Pieris Pharmaceuticals, Inc. stock-summary
stock-summary
Pieris Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
Company Coordinates stock-summary
Company Details
255 STATE STREET, 9TH FLOOR , BOSTON MA : 02109
stock-summary
Tel: 1 857 24689981 857 3629635
stock-summary
https://www.pieris.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."